We are live on ! Find out more
INO icon

Inovio Pharmaceuticals
INO

103 hedge funds and large institutions have $20.7M invested in Inovio Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 23 increasing their positions, 29 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,384% more call options, than puts

Call options by funds: $1.4M | Put options by funds: $94K

4% less funds holding

Funds holding: 107 → 103 (-4)

7% less capital invested

Capital invested by funds: $22.2M → $20.7M (-$1.47M)

9.36% less ownership

Funds ownership: 37.09% → 27.73% (-9.4%)

14% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 28

21% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 29

Holders
103
Holders Change
-4
Holders Change %
-3.74%
% of All Funds
1.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
23
Reduced
29
Closed
28
Calls
$1.4M
Puts
$94K
Net Calls
+$1.3M
Net Calls Change
+$904K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$665K
2
Renaissance Technologies
Renaissance Technologies
New York
+$541K
3
CSS
Cubist Systematic Strategies
Connecticut
+$329K
4
Citadel Advisors
Citadel Advisors
Florida
+$324K
5
GCP
GSA Capital Partners
United Kingdom
+$313K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.41M
2
DTC
Deep Track Capital
Connecticut
-$2.18M
3
SCM
Stonepine Capital Management
Oregon
-$845K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$784K
5
State Street
State Street
Massachusetts
-$748K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jones Financial Companies
76
Jones Financial Companies
Missouri
$519 +$437 +228 +1,267%
ANBT
77
American National Bank & Trust
Texas
$407 – – –
BCM
78
Blume Capital Management
California
$169 – – –
Barclays
79
Barclays
United Kingdom
$167 -$69.6K -36,327 -100%
PAI
80
Pittenger & Anderson Inc
Nebraska
$157 – – –
US Bancorp
81
US Bancorp
Minnesota
$126 -$17 -9 -13%
National Bank of Canada
82
National Bank of Canada
Quebec, Canada
$110 +$2 +1 +2%
TWC
83
TD Waterhouse Canada
Ontario, Canada
$94 – – –
1NWS
84
1 North Wealth Services
Maryland
$83 – – –
EWA
85
EverSource Wealth Advisors
Alabama
$81 -$299 -156 -80%
Northwestern Mutual Wealth Management
86
Northwestern Mutual Wealth Management
Wisconsin
$77 +$73 +38 New
SWP
87
Strategic Wealth Partners
Ohio
$59 +$56 +29 New
AP
88
Atwood & Palmer
Missouri
$37 – – –
CA
89
CoreCap Advisors
Michigan
$33 -$2.57K -1,340 -99%
FFA
90
Farther Finance Advisors
California
$33 – – –
TWD
91
True Wealth Design
Ohio
$31 +$29 +15 New
IA
92
IFP Advisors
Florida
$28 +$27 +14 New
KFI
93
Key Financial Inc
Pennsylvania
$28 +$27 +14 New
TIM
94
Thompson Investment Management
Wisconsin
$26 – – –
GSWM
95
Golden State Wealth Management
California
$20 – – –
JFGIW
96
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$17 +$15 +8 New
LFG
97
Larson Financial Group
Missouri
$16 – – –
NSIM
98
North Star Investment Management
Illinois
$14 – – –
AFG
99
Albion Financial Group
Utah
$11 – – –
GWSG
100
GPS Wealth Strategies Group
Colorado
$8 – – –
2 3
4
5 6

INO Hedge Fund Activity: Q2 2025 in Review

103 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2025, worth a combined $20.7M — down 6.6% from $22.2M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of INO and 24 opened new positions — a net loss of 4 holders — while 29 trimmed existing stakes and 23 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $665K. The largest seller was BlackRock, cutting an estimated $3.41M.

  • 103 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2025, down from 107 in Q1 2025.
  • Funds reported $20.7M of Inovio Pharmaceuticals stock for Q2 2025, down 6.6% quarter-over-quarter.
  • 24 funds opened new Inovio Pharmaceuticals positions in Q2 2025 and 28 closed out, a net change of -4 holders.
  • The largest Inovio Pharmaceuticals buyer in Q2 2025 was Millennium Management, an estimated $665K added.
  • The largest Inovio Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $3.41M sold.

Based on aggregated 13F filings for Q2 2025.